Last updated on February 2018

Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml

Brief description of study

This cross-over study will investigate the efficacy and safety of BIMMD and TUDPF in a clinical setting.

Detailed Study Description

  • A prospective, randomized, investigator-masked, crossover comparison;
    • Ocular hypertension or glaucoma (XFG or POAG) patients and who consent to participate will be enrolled in this study
    • Patients will be scheduled for a screening visit IOP assessment (IOP measurements at 08:30, 12:30 and 16:30 (1 hour).
    • Patients who are on therapy at the screening visit and who consent to participate will undergo a washout period for 4 weeks (depending on therapy) before the baseline visit;
    • Patient can under the washout period be given brinzolamide (Azopt) if needed, Azopt should then be discontinued 5 days before baseline visit;
    • After the screening visit (and after wash-outperiod for treated patients) patients will be scheduled to undergo a baseline visit IOP assessment (IOP measurements at 08:30, 12:30 and 16:30 ( 1 hour with a minimum of 3 hours between readings) and will then be randomized for Period 1 to receive either BIMMD drops once in the evening (20:30) or TUDPF drops once in the evening (20:30) for 3 month
    • After 3 month, patients will be switched for Period 2, to the opposite treatment (e.g. switched to either BIMMD or TUDPF) to be dosed in the evening;
    • After another 3 months they will undergo the final evaluation of IOP levels and of tolerability;
    • Intermediate safety visits may be scheduled at the discretion of the investigator.

Clinical Study Identifier: NCT02471105

Contact Investigators or Research Sites near you

Start Over

Anton Hommer

Hommer Ophthalmology Institute
Vienna, Austria
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.